duvelisib
Showing 26 - 33 of 33
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Duvelisib)
Withdrawn
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Duvelisib
-
Tempe, Arizona
- +7 more
Mar 15, 2021
CD20+ Follicular Lymphoma Trial in Worldwide (Duvelisib, Rituximab, Obinutuzumab)
Terminated
- CD20+ Follicular Lymphoma
- Duvelisib
- +2 more
-
Los Angeles, California
- +20 more
Mar 15, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Duvelisib, Ofatumumab)
Completed
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Duvelisib
- Ofatumumab
-
La Jolla, California
- +91 more
Dec 14, 2021
Indolent Non-Hodgkin Lymphoma Trial in Worldwide (Duvelisib)
Active, not recruiting
- Indolent Non-Hodgkin Lymphoma
- Duvelisib
-
Los Angeles, California
- +68 more
Mar 15, 2021
Indolent Non-hodgkin Lymphoma Trial in Worldwide (Duvelisib)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
- Duvelisib
-
Washington, District of Columbia
- +39 more
May 17, 2021
Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin Trial in United States (duvelisib, PI3K inhibitor)
Terminated
- Lymphoma, Small Lymphocytic
- +4 more
- duvelisib
- PI3K inhibitor
-
Little Rock, Arkansas
- +10 more
Mar 15, 2021
Lymphoma Trial in Aichi, Fukuoka, Tokyo (duvelisib)
Completed
- Lymphoma
- duvelisib
-
Aichi, Japan
- +2 more
Feb 3, 2017
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma Trial in United States (Duvelisib, Venetoclax)
Withdrawn
- Chronic Lymphocytic Leukemia
- +2 more
- Duvelisib
- Venetoclax
-
Tucson, Arizona
- +9 more
Jul 22, 2016